Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7R  Dependent

(2015) C. B. Johnson et al.   Cancer Immunology Research

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

(2015) Danielle M Lussier et al.   Journal for ImmunoTherapy of Cancer

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

(2013) S. K. Perna et al.   CLINICAL CANCER RESEARCH

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibitory role of the transcription repressor Gfi1 in the generation of thymus-derived regulatory T cells

(2013) Lewis Zhichang Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

IL-7 Abrogates Suppressive Activity of Human CD4+CD25+FOXP3+ Regulatory T Cells and Allows Expansion of Alloreactive and Autoreactive T Cells

(2012) A.-K. Heninger et al.   JOURNAL OF IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)

(2010) Tyler R Simpson et al.   CURRENT OPINION IN IMMUNOLOGY

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Induction of an IL7-R+c-Kithi myelolymphoid progenitor critically dependent on IFN-γ signaling during acute malaria

(2010) Nikolai N Belyaev et al.   NATURE IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung Cancer

(2009) A. Andersson et al.   JOURNAL OF IMMUNOLOGY

IL-7 Receptor Expression Provides the Potential for Long-Term Survival of Both CD62Lhigh Central Memory T Cells and Th1 Effector Cells during Leishmania major Infection

(2009) S. L. Colpitts et al.   JOURNAL OF IMMUNOLOGY

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

(2009) Marc Pellegrini et al.   NATURE MEDICINE

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

(2008) A. Ribas et al.   CLINICAL CANCER RESEARCH

Homeostasis of Naive and Memory T Cells

(2008) Charles D. Surh et al.   IMMUNITY

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

(2008) Claude Sportès et al.   JOURNAL OF EXPERIMENTAL MEDICINE